Clinical trial
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple…
NCT00440635 · Janssen-Cilag International NV, Industry · Completed
Key facts
| NCT number | NCT00440635 |
|---|---|
| Title | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma |
| Official title | International Single-Arm Protocol to Provide Expanded Access to Bortezomib for Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma |
| Lead sponsor | Janssen-Cilag International NV, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, tradename Velcade |
| Enrollment | 641 |
| Start date | Jan 1, 2004 |
| Completion | Oct 1, 2006 |
| First posted | Feb 27, 2007 |
| Last update posted | Apr 16, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: